Protease inhibitor treats DR

Article

ASP-440 - a protease, developed by ActiveSite Pharmaceuticals and an inhibitor of plase kallikrein - may provide an effective therapeutic treatment for diabetic retinopathy (DR), according to study results published in the February 2009 issue of Hypertension.

ASP-440 - a protease, developed by ActiveSite Pharmaceuticals and an inhibitor of plase kallikrein - may provide an effective therapeutic treatment for diabetic retinopathy (DR), according to study results published in the February 2009 issue of Hypertension.

Edward P. Feener, PhD of Harvard Medical School and the Joslin Diabetes Center, Boston, US and colleagues tested ASP-440 through continuous systemic administration to rodents whose vasculature had been compromised by hypertension.

In the animal model, ASP-440 reduced the permeability of the retinal vasculature by up to 70%, and also reduced elevated blood pressure.

The team concluded that, by reducing retinal permeability through inhibition of kallikrein, ASP-440 may be able to reduce the incidence of diabetic macular oedema and diabetic retinopathy.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.